OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kris on the Impact of Bevacizumab Biosimilars in Lung Cancer

October 23rd 2019

Mark G. Kris, MD, discusses the impact biosimilars for bevacizumab (Avastin) could have in lung cancer.

Dr. Akerley on MET Biomarker in Lung Cancer

October 23rd 2019

Wallace L. Akerley, MD, discusses using MET as a biomarker in lung cancer.

Dr. Perl on Challenges of Implementing Immunotherapy in AML

October 23rd 2019

Alexander E. Perl, MD, MS, discusses the challenges of using immunotherapy with antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies in acute myeloid leukemia.

Dr. Mahoney on Potential of VISTA-Targeting Therapy in RCC

October 23rd 2019

Kathleen Mahoney, MD, PhD, discusses the potential of targeting V-domain immunoglobulin containing suppressor of T-cell activation in renal cell carcinoma.

Dr. Siddiqi on Rationale for the TRANSCEND CLL 004 Trial in CLL/SLL

October 23rd 2019

Tanya Siddiqi, MD, discusses the rationale for the phase I/II TRANSCEND CLL 004 trial investigating the use of the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Preeshagul on Education for Biosimilars in Oncology

October 22nd 2019

Isabel Preeshagul, DO, MBS, discusses the need for more information about using biosimilars when treating patients with cancer.

Dr. Frey on Measuring MRD Throughout Treatment for ALL

October 22nd 2019

Noelle Frey, MD, MSCE, discusses measuring minimal residual disease throughout treatment for patients with acute lymphocytic leukemia.

Dr. Offin on Potential Implications of Introducing Biosimilars Into Oncology

October 22nd 2019

Michael D. Offin, MD, discusses the potential implications of introducing biosimilars into the field of oncology.

Dr. Singh on Combination Therapy in Localized Bladder Cancer

October 22nd 2019

Parminder Singh, MD, discusses combination treatments that are being evaluated in localized bladder cancer.

Dr. Pettaway on Importance of Inclusive Germline Testing in Prostate Cancer

October 22nd 2019

Curtis A. Pettaway, MD, discusses the need to include the genomic data of African American, Asian, and Hispanic men with prostate cancer in national registries.

Dr. Benson on the Use of Genomic Testing in Newly Diagnosed mCRC

October 22nd 2019

Al B. Benson, MD, discusses the use of genomic testing in patients with newly diagnosed metastatic colorectal cancer.

Dr. Mato on Immunotherapy Options in CLL

October 22nd 2019

Anthony R. Mato, MD, MSCE, discusses the current immunotherapy options for patients with chronic lymphocytic leukemia.

Dr. Yorio on T-DM1 in HER2-Mutant Lung Cancer Treatment

October 22nd 2019

Jeff Yorio, MD, discusses a small phase II study that is looking at using ado-trastuzumab emtansine to treat patients with HER2-mutant metastatic lung cancer.

Dr. Gibbs on Predicting Response to Treatment in Osteosarcoma

October 21st 2019

C. Parker Gibbs Jr., MD, discusses the use of cell cycle checkpoint regulators to indicate response to treatment in osteosarcoma.

Dr. Gonzalez-Martin on Rationale for Phase III PRIMA Trial in Advanced Ovarian Cancer

October 21st 2019

Antonio Gonzalez-Martin, MD, discusses the rationale for the phase III PRIMA trial investigating niraparib (Zejula) as maintenance therapy for patients with platinum-sensitive advanced ovarian cancer.

Dr. Wierda on Using CD19-Targeted CAR T Cells in CLL

October 21st 2019

William G. Wierda, MD, PhD, discusses the use of CD19-targeted CAR T-cell therapy in the treatment of patients with chronic lymphocytic leukemia.

Dr. McGregor on Unmet Needs in Non-Clear Cell RCC

October 21st 2019

Bradley McGregor, MD, discusses the challenges of developing treatment strategies for patients with non-cell clear renal cell carcinoma.

Dr. Marks on Investigational Antibody-Drug Conjugates in HER2+ Breast Cancer

October 21st 2019

Douglas K. Marks, MD, discusses investigational antibody–drug conjugates in HER2-positive breast cancer.

Dr. Richards on Genetic Testing in Metastatic Pancreatic Cancer

October 21st 2019

Donald A. Richards, MD, PhD, discusses the use of genetic testing in patients with metastatic pancreatic cancer.

Dr. Long on Sequencing Local Therapy in Patients With Melanoma Who Have Brain Mets

October 21st 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the sequence of local therapy in patients with melanoma who have brain metastases.